JP2013541587A - Nedd8活性化酵素阻害剤の投与 - Google Patents

Nedd8活性化酵素阻害剤の投与 Download PDF

Info

Publication number
JP2013541587A
JP2013541587A JP2013537807A JP2013537807A JP2013541587A JP 2013541587 A JP2013541587 A JP 2013541587A JP 2013537807 A JP2013537807 A JP 2013537807A JP 2013537807 A JP2013537807 A JP 2013537807A JP 2013541587 A JP2013541587 A JP 2013541587A
Authority
JP
Japan
Prior art keywords
mln4924
use according
cancer
day
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013537807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541587A5 (cg-RX-API-DMAC7.html
Inventor
ブルース ジェイ. デズーベ,
リリ エム. ペトルゼリ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2013541587A publication Critical patent/JP2013541587A/ja
Publication of JP2013541587A5 publication Critical patent/JP2013541587A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013537807A 2010-11-05 2011-11-03 Nedd8活性化酵素阻害剤の投与 Pending JP2013541587A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41047810P 2010-11-05 2010-11-05
US61/410,478 2010-11-05
US201161488240P 2011-05-20 2011-05-20
US61/488,240 2011-05-20
PCT/US2011/059060 WO2012061551A1 (en) 2010-11-05 2011-11-03 Administration of nedd8-activating enzyme inhibitor

Publications (2)

Publication Number Publication Date
JP2013541587A true JP2013541587A (ja) 2013-11-14
JP2013541587A5 JP2013541587A5 (cg-RX-API-DMAC7.html) 2014-12-18

Family

ID=46020229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537807A Pending JP2013541587A (ja) 2010-11-05 2011-11-03 Nedd8活性化酵素阻害剤の投与

Country Status (4)

Country Link
US (2) US20120115892A1 (cg-RX-API-DMAC7.html)
EP (1) EP2635287A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013541587A (cg-RX-API-DMAC7.html)
WO (1) WO2012061551A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017111074A1 (ja) * 2015-12-22 2017-06-29 大鵬薬品工業株式会社 ピロロピリミジン化合物による抗腫瘍効果増強剤

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188881A1 (en) * 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
US9200333B2 (en) 2012-07-25 2015-12-01 Indiana University Research And Technology Corporation Methods for identifying modulators of murine double minute 2
CN105407973A (zh) * 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与
CN106661031B (zh) * 2014-06-24 2019-07-23 大鹏药品工业株式会社 吡咯并嘧啶化合物或其盐、含有其的药物组合物及应用
CN108210497B (zh) * 2016-12-21 2019-12-20 天津大学 化合物mln4924在制备布尼亚病毒科白蛉病毒属病毒抑制剂的应用
US20220133884A1 (en) * 2019-02-26 2022-05-05 Millennium Pharmaceuticals, Inc. Compounds useful as adjuvants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038701A2 (en) * 2007-09-17 2009-03-26 Schering Corporation Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
EP2540727B1 (en) * 2007-08-02 2018-07-25 Millennium Pharmaceuticals, Inc. Sulfamoylating reagent
EP2430026A1 (en) * 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038701A2 (en) * 2007-09-17 2009-03-26 Schering Corporation Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN7015002695; 'View of NCT01011530 on 2010_10_18' ClinicalTrials.gov archive , 20101018 *
JPN7015002696; SHAH, Jatin J et al: 'Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma a' 51th ASH ANNUAL MEETING AND EXPOSITION , 20091203 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017111074A1 (ja) * 2015-12-22 2017-06-29 大鵬薬品工業株式会社 ピロロピリミジン化合物による抗腫瘍効果増強剤
JPWO2017111074A1 (ja) * 2015-12-22 2018-05-10 大鵬薬品工業株式会社 ピロロピリミジン化合物による抗腫瘍効果増強剤

Also Published As

Publication number Publication date
US20120115892A1 (en) 2012-05-10
EP2635287A4 (en) 2014-06-04
US20140249167A1 (en) 2014-09-04
WO2012061551A1 (en) 2012-05-10
EP2635287A1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
CN104245699B (zh) Nedd8‑活化酶抑制剂和低甲基化剂的投与
US20120115892A1 (en) Administration of nedd8-activating enzyme inhibitor
BR112021006033A2 (pt) Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina
JP7522661B2 (ja) ビスフルオロアルキル-1,4-ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
JP5028480B2 (ja) 手足症候群の治療のためのアロプリノールの使用
KR20210008527A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 및 이의 사용 방법
IL278721B1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
US20250064824A1 (en) Administration of aurora kinase inhibitor and chemotherapeutic agents
WO2011125763A1 (ja) 手足症候群の予防および/または治療剤
JP4761000B1 (ja) 手足症候群の予防および/または治療剤
JP4983989B2 (ja) 手足症候群の予防および治療剤
WO2018144791A1 (en) Combination of vps34 inhibitors and mtor inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160318